Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Non-invasive assessment of non-alcoholic fatty liver disease: Clinical prediction rules and blood-based biomarkers
Eduardo Vilar‐Gómez, Naga Chalasani
Journal of Hepatology (2017) Vol. 68, Iss. 2, pp. 305-315
Closed Access | Times Cited: 522

Showing 1-25 of 522 citing articles:

Noninvasive Assessment of Liver Disease in Patients With Nonalcoholic Fatty Liver Disease
Laurent Castéra, Mireen Friedrich‐Rust, Rohit Loomba
Gastroenterology (2019) Vol. 156, Iss. 5, pp. 1264-1281.e4
Open Access | Times Cited: 1150
Gut microbiota and human NAFLD: disentangling microbial signatures from metabolic disorders
Judith Aron‐Wisnewsky, Chloé Vigliotti, Julia J. Witjes, et al.
Nature Reviews Gastroenterology & Hepatology (2020) Vol. 17, Iss. 5, pp. 279-297
Open Access | Times Cited: 759
Organ and tissue fibrosis: Molecular signals, cellular mechanisms and translational implications
Ralf Weiskirchen, Sabine Weiskirchen, Frank Tacke
Molecular Aspects of Medicine (2018) Vol. 65, pp. 2-15
Closed Access | Times Cited: 458
Adaptive immunity: an emerging player in the progression of NAFLD
Salvatore Sutti, Emanuele Albano
Nature Reviews Gastroenterology & Hepatology (2019) Vol. 17, Iss. 2, pp. 81-92
Open Access | Times Cited: 303
Evaluation of the effects of dapagliflozin, a sodium‐glucose co‐transporter‐2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non‐alcoholic fatty liver disease
Masanori Shimizu, Kunihiro Suzuki, Kanako Kato, et al.
Diabetes Obesity and Metabolism (2018) Vol. 21, Iss. 2, pp. 285-292
Closed Access | Times Cited: 302
Limitations of non-invasive tests for assessment of liver fibrosis
Keyur Patel, Giada Sebastiani
JHEP Reports (2020) Vol. 2, Iss. 2, pp. 100067-100067
Open Access | Times Cited: 226
Global Epidemiology, Prevention, and Management of Hepatocellular Carcinoma
Lung‐Yi Mak, Vania Cruz-Ramón, Paulina Chinchilla-López, et al.
American Society of Clinical Oncology Educational Book (2018), Iss. 38, pp. 262-279
Closed Access | Times Cited: 206
Risk of severe illness from COVID-19 in patients with metabolic dysfunction-associated fatty liver disease and increased fibrosis scores
Giovanni Targher, Alessandro Mantovani, Christopher D. Byrne, et al.
Gut (2020) Vol. 69, Iss. 8, pp. 1545-1547
Open Access | Times Cited: 194
Nonalcoholic Fatty Liver Disease in Adults: Current Concepts in Etiology, Outcomes, and Management
Thomas Marjot, Ahmad Moolla, Jeremy Cobbold, et al.
Endocrine Reviews (2019) Vol. 41, Iss. 1, pp. 66-117
Open Access | Times Cited: 190
Epidemiology, Pathogenesis, Diagnosis and Emerging Treatment of Nonalcoholic Fatty Liver Disease
Evangelia Makri, A. Goulas, Stergios A. Pοlyzos
Archives of Medical Research (2020) Vol. 52, Iss. 1, pp. 25-37
Closed Access | Times Cited: 163
Liver Fibrosis in Non-alcoholic Fatty Liver Disease: From Liver Biopsy to Non-invasive Biomarkers in Diagnosis and Treatment
Leen Heyens, Dana Busschots, Ger H. Koek, et al.
Frontiers in Medicine (2021) Vol. 8
Open Access | Times Cited: 161
Current treatment of non‐alcoholic fatty liver disease
Rafael Paternostro, Michael Trauner
Journal of Internal Medicine (2022) Vol. 292, Iss. 2, pp. 190-204
Open Access | Times Cited: 151
Repeated FIB-4 measurements can help identify individuals at risk of severe liver disease
Hannes Hagström, Mats Talbäck, Anna Andréasson, et al.
Journal of Hepatology (2020) Vol. 73, Iss. 5, pp. 1023-1029
Open Access | Times Cited: 150
Development and Validation of Hepamet Fibrosis Scoring System–A Simple, Noninvasive Test to Identify Patients With Nonalcoholic Fatty Liver Disease With Advanced Fibrosis
Javier Ampuero, Raluca Pais, R. Aller, et al.
Clinical Gastroenterology and Hepatology (2019) Vol. 18, Iss. 1, pp. 216-225.e5
Open Access | Times Cited: 149
Ability of Noninvasive Scoring Systems to Identify Individuals in the Population at Risk for Severe Liver Disease
Hannes Hagström, Mats Talbäck, Anna Andréasson, et al.
Gastroenterology (2019) Vol. 158, Iss. 1, pp. 200-214
Closed Access | Times Cited: 149
Intestinal Virome Signature Associated With Severity of Nonalcoholic Fatty Liver Disease
Sonja Lang, Münevver Demir, Anna Martin, et al.
Gastroenterology (2020) Vol. 159, Iss. 5, pp. 1839-1852
Open Access | Times Cited: 148
Nonalcoholic Fatty Liver Disease in Diabetes. Part I: Epidemiology and Diagnosis
Yong‐ho Lee, Yongin Cho, Byung‐Wan Lee, et al.
Diabetes & Metabolism Journal (2019) Vol. 43, Iss. 1, pp. 31-31
Open Access | Times Cited: 145
NAFLD, Insulin Resistance, and Diabetes Mellitus Type 2
Marinko Marušić, Matej Paić, Mia Knobloch, et al.
Canadian Journal of Gastroenterology and Hepatology (2021) Vol. 2021, pp. 1-9
Open Access | Times Cited: 132
Epidemiological trends and trajectories of MAFLD-associated hepatocellular carcinoma 2002–2033: the ITA.LI.CA database
Alessandro Vitale, Gianluca Svegliati‐Baroni, Alessio Ortolani, et al.
Gut (2021) Vol. 72, Iss. 1, pp. 141-152
Closed Access | Times Cited: 116
Type 2 diabetes mellitus increases the risk of hepatic fibrosis in individuals with obesity and nonalcoholic fatty liver disease
Diana Barb, Enrico Repetto, Michael Edward Stokes, et al.
Obesity (2021) Vol. 29, Iss. 11, pp. 1950-1960
Open Access | Times Cited: 112
Non-invasive diagnosis and monitoring of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis
Monica A. Tincopa, Rohit Loomba
˜The œLancet. Gastroenterology & hepatology (2023) Vol. 8, Iss. 7, pp. 660-670
Closed Access | Times Cited: 77
Risk assessment with gut microbiome and metabolite markers in NAFLD development
Howell Leung, Xiaoxue Long, Yueqiong Ni, et al.
Science Translational Medicine (2022) Vol. 14, Iss. 648
Open Access | Times Cited: 76
Head-to-head comparison between MEFIB, MAST, and FAST for detecting stage 2 fibrosis or higher among patients with NAFLD
Beom Kyung Kim, Nobuharu Tamaki, Kento Imajo, et al.
Journal of Hepatology (2022) Vol. 77, Iss. 6, pp. 1482-1490
Open Access | Times Cited: 72
Association of per- and polyfluoroalkyl substance exposure with fatty liver disease risk in US adults
Xinyuan Zhang, Longgang Zhao, Alan Ducatman, et al.
JHEP Reports (2023) Vol. 5, Iss. 5, pp. 100694-100694
Open Access | Times Cited: 53
Tissue fibrosis induced by radiotherapy: current understanding of the molecular mechanisms, diagnosis and therapeutic advances
Zuxiang Yu, Chaoyu Xu, Bin Song, et al.
Journal of Translational Medicine (2023) Vol. 21, Iss. 1
Open Access | Times Cited: 44
Page 1 - Next Page

Scroll to top